NEUROCRINE BIOSCIENCES INC
For the period ended Dec 31, 2024. Filed Feb 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 10, 2025
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Income and Comprehensive Income
CONSOLIDATED STATEMENTS INCOME
AND COMPREHENSIVE INCOME
| Year Ended December 31, | |||
|---|---|---|---|
| (in millions, except per share data) | 2024 | 2023 | 2022 |
| Revenues: | |||
| Net product sales | $2,330.6 | $1,860.6 | $1,440.9 |
| Collaboration revenue | 24.7 | 26.5 | 47.8 |
| Total revenues | 2,355.3 | 1,887.1 | 1,488.7 |
| Operating expenses: | |||
| Cost of revenues | 34.0 | 39.7 | 23.2 |
| Research and development | 731.1 | 565.0 | 463.8 |
| Acquired in-process research and development | 12.5 | 143.9 | — |
| Selling, general, and administrative | 1,007.2 | 887.6 | 752.7 |
| Total operating expenses | 1,784.8 | 1,636.2 | 1,239.7 |
| Operating income | 570.5 | 250.9 | 249.0 |
| Other (expense) income: | |||
| Unrealized (loss) gain on equity investments | (37.1) | 28.4 | 30.8 |
| Charges associated with convertible senior notes | (138.4) | — | (70.0) |
| Interest income and other, net | 91.0 | 52.8 | 4.1 |
| Total other (expense) income, net | (84.5) | 81.2 | (35.1) |
| Income before provision for income taxes | 486.0 | 332.1 | 213.9 |
| Provision for income taxes | 144.7 | 82.4 | 59.4 |
| Net income | 341.3 | 249.7 | 154.5 |
| Foreign currency translation adjustments, net of tax | (1.1) | 2.4 | 2.9 |
| Unrealized gain (loss) on available-for-sale debt securities, net of tax | (0.1) | 12.5 | (9.1) |
| Comprehensive income | $340.1 | $264.6 | $148.3 |
| Earnings per share, basic | $3.40 | $2.56 | $1.61 |
| Earnings per share, diluted | $3.29 | $2.47 | $1.56 |
| Weighted average common shares outstanding, basic | 100.4 | 97.7 | 95.8 |
| Weighted average common shares outstanding, diluted | 103.7 | 101.0 | 98.9 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.